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Although conventional vaccines have generated major successes in the control of infectious diseases, several
obstacles remain in their development against chronic diseases (HIV, tuberculosis), against which no current
candidate vaccines yet ensure protection. The transcutaneous route of vaccine administration appears to be a
promising approach of targeting vaccines toward antigen-presenting cells (APCs) and thus improving immune
responses. We investigated the suitability of nanoparticles in this approach. We found a high density of
Langerhans cells (LCs) around hair follicles that, when sorted, readily internalized all size particles. However,
flow cytometry after transcutaneous application of 40, 750, or 1,500 nm nanoparticles on human skin samples
revealed that only 40 nm particles entered epidermal LC. Fluorescence and laser scan microscopies, which were
carried out to identify the penetration pathway of transcutaneously applied nanoparticles, revealed that only
40 nm particles deeply penetrate into vellus hair openings and through the follicular epithelium. We conclude
that 40 nm nanoparticles, but not 750 or 1,500 nm nanoparticles, may be efficiently used to transcutaneously
deliver vaccine compounds via the hair follicle into cutaneous APCs.
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INTRODUCTION
Vaccines have generated major successes in the control of
infectious diseases, but several obstacles remain in the
development of vaccines against pandemic chronic diseases,
such as HIV or tuberculosis, or in the access to vaccines in
developing countries which require safe, well-tolerated, and
easy-to-use vaccines. Transcutaneous vaccine delivery offers
an advantageous mode of immunization due to the unique
ability of cutaneous immune cells, especially Langerhans
cells (LCs), to present antigens to the immune system. It is
known that strong and efficient immune responses can be
induced by targeting vaccines to skin antigen-presenting cells
(APCs) (Guebre-Xabier et al., 2003; Partidos et al., 2003). For
example, Kenney et al. (2004) reported that the intradermal
administration of one-fifth of the standard intramuscular dose
of an influenza vaccine elicited immunogenicity that was
similar to or better than that elicited by conventional
intramuscular injection. Recent studies further revealed that
vaccination is possible even through intact skin, for example,
by patch application (Glenn et al., 2000). Thus, dermal or
transdermal delivery of vaccines has provided a great
opportunity for further development.
Innovative preparations of vaccines, such as adsorption to
nanoparticles, may as well help improve the efficacy of
current vaccination strategies. According to Scheicher et al.
(1995), the uptake of particle-bound antigen by bone
marrow-derived dendritic cells triggers their activation and
increases their antigen presentation capacity compared to
free, that is, not particle-bound, antigen. Shen et al. (1997)
found in cloned dendritic cells that the presentation of
exogenous ovalbumin was markedly enhanced when the
antigen was particulate. Similarly, particle-mediated immu-
nization of pigs with plasmid DNA expressing the influenza A
hemagglutinin resulted in protection against the following
challenge, which was equivalent to or better than a com-
mercial swine influenza vaccine (Macklin et al., 1998). In this
study, we investigated the penetration profile of 40, 750, and
1,500 nm nanoparticles on human skin samples by transcu-
taneous route and their possible targeting to APCs of the skin.
RESULTS
40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal
CD1aþ cells after transcutaneous application on human skin
In order to define the cell type accessible to nanoparticles
that enter human skin transcutaneously, we carried out
ORIGINAL ARTICLE
1316 Journal of Investigative Dermatology (2006), Volume 126 & 2006 The Society for Investigative Dermatology
Received 16 August 2005; revised 9 December 2005; accepted 3 January
2006; published online 13 April 2006
1Department of Dermatology and Allergy, Clinical Research Center for Hair
and Skin Physiology, Charite-Universita¨tsmedizin Berlin, Berlin, Germany
and 2Laboratoire d’ Immunologie Cellulaire et Tissulaire, Hopital Pitie
Salpetriere, Universite Pierre et Marie Curie, Paris, France
Correspondence: Dr Annika Vogt, Department of Dermatology and Allergy,
Clinical Research Center for Hair and Skin Physiology,
Charite-Universita¨tsmedizin Berlin, Berlin, Germany.
E-mail: annika.vogt@charite.de
Abbreviations: APC, antigen-presenting cell; CD, cluster of differentiation;
CSSS, cyanacrylate skin surface stripping; LC, Langerhans cell
PBS, phosphate-buffered saline
staining of LCs with anti-cluster of differentiation (CD)1a on
human skin samples from healthy volunteers undergoing
plastic surgery. We showed a major concentration of
CD1aþ cells in the epithelium of a vellus hair follicle infun-
dibulum (Figure 1a). These cells also present LC/dendritic
cell morphology, as shown in Figure 1b.
Cyanacrylate skin surface stripping (CSSS) improves the
follicular penetration of transcutaneously applied compounds
by removing keratinized material, lipids, and other cell debris
from the follicular openings, and, occasionally, hair fibers,
especially vellus hairs (Mills and Kligman, 1983; Schaefer
and Lademann, 2001). One CSSS further removes approx.
30% of the stratum corneum; the remaining stratum corneum
and the viable interfollicular epidermis are left intact. After
CSSS, 40, 750, or 1,500 nm nanoparticles in aqueous solution
were applied on the skin surface, the skin samples were
incubated in a humidified chamber at 371C for 16 hours. LCs
were isolated by magnetic cell sorting (MACS) and revealed
that only CD1a þ cells from skin samples treated with 40 nm
nanoparticles, and not 750 nm and 1,500 nm particles,
exhibited nanoparticle-associated fluorescence (Figure 2).
The percentage of CD1aþparticleþ cells was 24.3715.9%
(Figure 2a) compared to control samples. Microscopically,
we identified a granular fluorescent staining pattern inside
CD1aþ cells, which was highly suggestive for uptake and
internalization of the nanoparticles (Figure 2b). In contrast,
only 0.4% cells separated from skin samples treated with 750
or 1,500 nm nanoparticles were nanoparticle-positive (Figure
2c and d).
We, thus, showed that LCs, which form a tight meshwork
within the epidermis, and which can also be found at high
densities around hair follicles, are capable of internalizing
40 nm, but not 750 nm and 1,500 nm, particles when applied
transcutaneously.
In vitro isolated LC uptake of 40, 750 and 1,500 nm particles
To verify whether LC suspensions, at all, internalize the
nanoparticles, we incubated MACS-separated epidermal LCs
for 2.5 hours in the presence of 40, 750, or 1,500 nm
nanoparticles. Consistent with previous findings by other
groups (Reis e Sousa et al., 1993; Reece et al., 2001), we
found a strong increase in cell-associated fluorescence by
flow cytometry analysis in all the samples (Figure 3a, d, and
g). Fluorescence microscopy of individual cells showed a
granular fluorescent staining indicating uptake and inter-
nalization not only of 40 nm, but also of 750 and 1,500 nm
nanoparticles by LCs (Figure 3b, e, and h).
When experiments were performed at 01C, cell-associated
fluorescence, albeit less intense and not granular, was also
found in samples. Microscopic evaluation of these control
samples revealed a homogeneous staining pattern confined to
the cell borders (Figure 3c) or limited to nanoparticle clusters
floating in the cell culture medium, which was highly
suggestive for nonspecific adherence of the nanoparticles to
the cell surface (Figure 3f and i).
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Figure 1. CD1a-positive cells in the epithelium of a human vellus hair
follicle infundibulum. Immuofluorescent staining was performed using
anti-CD1a-FITC antibody. (a) CD1a-positive cells were found at high
densities in the epithelium of the human vellus hair follicle infundibulum
(original magnification  20). (b) These cells also presented LC morphology
(original magnification  100). (a) Bar¼100 mm.
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Figure 2. Up-take of 40 nm nanoparticles by epidermal CD1aþ cells after
transcutaneous application on human skin. Fluorescent 40 nm (0.1% solids,
2.84 1013 particles/ml), 750 nm (0.1% solids, 1.08 1010 particles/ml) or
1,500 nm (0.1% solids, 1.35109 particles/ml) nanoparticles were applied
transcutaneously on human skin samples after CSSS. After incubation in a
humidified chamber at 371C for 16 hours, epidermal LCs were separated from
the epidermis by MACS separation, stained for CD1a and processed for flow
cytometry. In all, 10,000 events were acquired per sample. (a) The percentage
of cells CD1aþ particleþ cells are indicated in the upper right quadrant and
increased from 0% in the control samples to 24.3715.9% in skin samples
treated with 40 nm nanoparticles (n¼ 6 different donors). (b) These
fluorescent cells were also identified by fluorescence microscopy of LC
isolates, which showed a granular staining pattern similar to the granular
pattern seen after in vitro incubation of nanoparticles with isolated LCs
(original magnification  100). The percentage of cells CD1aþ particleþ
cells separated from skin treated with 750 nm (0.1% solids, 1.08 1010
particles/ml) or 1,500 nm (0.1% solids, 1.35109 particles/ml) nanoparticles
are indicated in the upper right quadrant of (c, d), respectively, and were
not significantly different from control samples (750 nm: 0.470.6% n¼3;
1,500 nm: 0.470.003% n¼3). (b) Bar¼ 5 mm.
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Penetration pathway of transcutaneously applied 40, 750, and
1,500 nm particles
In order to further elucidate the penetration pathway of
transcutaneously applied nanoparticles, we performed fluore-
scence microscopy on cryosections prepared from skin
samples treated with 40 nm (six different donors), 750 nm
(three different donors), or 1,500 nm nanoparticles (three
different donors), respectively. Each skin sample was split
into four blocks of 0.50.5 cm2 and cryosections from all
blocks were assessed for the presence of vellus hair follicles
by fluorescence microscopy. In all, 120 sections from skin
samples treated with 40 nm nanoparticles were analyzed, and
60 hair follicle sections were identified. Only the best section
of each hair follicle was chosen, subsequent sections of the
same hair follicle were excluded from the studies. In all
sections investigated by fluorescence microscopy, we found
40 nm nanoparticles penetrating to, at least, the entry level of
the sebaceous duct, which, according to our own measure-
ments on 76 vellus hair follicles, corresponds to a depth of
225734 mm (Figure 4a and b, Vogt et al., in preparation). In
all, 26 sections showing complete or almost complete
longitudinal sections of vellus hair follicles were analyzed
by laser scan microscopy, where we found 40 nm particles
penetrating all along the follicular duct, and occasionally 2–3
of 26, also directly into the perifollicular tissue. Fluorescent
staining in the dermis was found in 11 out of 26 sections. In
contrast, we did not observe nanoparticle-associated fluore-
scence either below the upper infundibulum or in the dermis,
in any of the skin samples treated with 750 or 1,500 nm
particles (three different donors each, 60 slides screened, 30
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Figure 3. Isolated epidermal LCs in suspension internalize 40, 750, and 1,500 nm nanoparticles. Freshly separated epidermal LCs in culture media were
incubated for 2.5 hours at 371C in the presence of fluorescent 40 nm (0.02% solids, 5.68 1010 particles/ml), 750 nm (0.02% solids, 2.16107 particles/ml), or
1,500 nm (0.02% solids, 2.7106 particles/ml) nanoparticles, respectively. The experiments were carried out at 371C and at 01C as indicated. (a, d, g) Flow
cytometry revealed a distinct increase in nanoparticle-related fluorescence in all investigated samples (10,000 events counted) (dotted line: negative control,
solid gray line: control at 01C, solid black line: 371C). (b, e, h) A granular pattern of fluorescence was observed by fluorescence microscopy on separated cells
indicating uptake of nanoparticles by epidermal LCs only at 371C (original magnification  100). In contrast, the fluorescence in control samples incubated
at 01C was (c) less intense, rather homogeneous and confined to the cell borders or (f, i) limited to nanoparticle clusters floating in the cell culture medium
(original magnification  100). (b, c, e, f, h, i) Bar¼5 mm.
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sections of hair follicles), although the fluorescence intensity
of individual particles of this size is much higher and easier to
detect than the fluorescence of 40 nm nanoparticles (Figure
4c–f). Our data confirm that only 40 nm particles penetrated
the skin via the follicular route and possibly into the
perifollicular dermis, thereby passing the close meshwork of
epidermal LCs, which are particularly concentrated in and
around the upper parts of human hair follicles as shown in
Figure 1 and other studies (Christoph et al., 2000; Taira et al.,
2002).
DISCUSSION
In this study, we were able to demonstrate that transcuta-
neously applied 40 nm nanoparticles, but not 750 or
1,500 nm, penetrated human skin and entered epidermal
CD1aþ cells in vitro. The interindividual variability of
nanoparticle penetration and uptake was high, and most
likely a result of factors such as immune status, age of the
donor, and modifications related to transport and processing
of the skin samples. However, the result of 24.3% nanopar-
ticle-positive cells in skin samples treated with 40 nm
nanoparticles compared to 0.4% in skin samples treated with
750 or 1,500 nm nanoparticles demonstrates clearly that only
40 nm nanoparticles were able to cross the skin barrier. In this
study, epidermal LCs served as a model cell population to
provide first proof of a concept for the use of nanoparticles in
transcutaneous vaccination. The immunological role of LCs
in transcutaneous vaccination, certainly, needs to be further
investigated, as well as the role of dermal APCs. Fluorescence
microscopy and laser scan microscopy results suggest that
transcutaneously applied 40 nm nanoparticles penetrated
predominantly via the follicular route into the perifollicular
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Figure 4. 40 nm, but not 750 or 1,500 nm, nanoparticles penetrate via the vellus hair follicle into the surrounding tissue. Laser scan microscopy were
performed on cryosections of skin samples treated with (a) 40 nm (0.1% solids, 2.841013 particles/ml, n¼6), (b) 750 nm (0.1% solids, 1.081010 particles/
ml), or (c) 1,500 nm (0.1% solids, 1.35109/ml) nanoparticles. Digital image overlay was used to localize the fluorescent signal on the tissue sections. This
figure shows exemplarily corresponding fluorescent microscopy images (black and white native image, red color corresponding to fluorescent signal, original
magnification  20) and laser scan microscopy images of the same hair follicles (black and green native image, red color indicates fluorescent signal, original
magnification  20). (a, b) We found that 40 nm nanoparticles, in contrast to the larger particles, penetrated deep into vellus hair follicles. (a) In addition,
laser scan microscopy revealed fluorescent signals in the adjacent tissue (*), indicating that the nanoparticles penetrated into and through the follicular
epithelium. Transcutaneously applied (c, d) 750 nm and (e, f) 1,500 nm fluorescent nanoparticles, in contrast, aggregated in the infundibulum of human vellus
hair follicles. No penetration to deeper parts of the hair follicles and no penetration into viable epidermis was observed in any of the samples. (a–f) Bar¼100 mm.
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dermis, thereby passing the close meshwork of follicular
APCs. In contrast, 750 and 1,500 nm nanoparticles aggre-
gated superficially in the hair follicle openings. Consistent
with the results obtained by flow cytometry, no deeper
penetration was observed and no fluorescent signals in the
dermis were observed in these samples. Our results are in
accordance with previous findings which showed that
nanoparticles, after application on the skin surface, aggregate
in follicular openings and penetrate along the follicular duct
(Rolland et al., 1993; Mordon et al., 2003). In fact, we
recently reported that the penetration depth of transcuta-
neously applied nanoparticles within the follicular duct of
scalp terminal hair follicles depends on the size of the
particles, suggesting that nanoparticles allow to selectively
target hair follicle compartments such as the entry level of the
sebaceous duct or the bulge region (‘‘Follicular Targeting’’)
(Toll et al., 2004; Vogt et al., 2005). The results presented in
this study validate our hypothesis of follicular targeting by
differently sized nanoparticles also in vellus hair follicle-
bearing skin. Moreover, we were able to demonstrate that, in
contrast to larger particles, 40 nm nanoparticles penetrate not
only into the hair follicle but also through the epithelium.
LCs can be found at particularly high densities in hair
follicle-bearing skin (Thomas et al., 1984). They are
particularly concentrated around the upper portion of the
hair follicles, where they are found not only in the suprabasal
layer but also in the basal layer of the outer root sheath
(Christoph et al., 2000; Taira et al., 2002). The loss of the
stratum corneum toward the lower part of the hair follicle
infundibulum implicates that APCs, which reside in and
around the hair follicle, are more accessible for topically
applied vaccines than APCs in the interfollicular epidermis,
which are shielded by the stratum corneum. Targeting of
vaccine to the hair follicle and to follicular APCs may, hence,
improve the efficacy of transcutaneous vaccination. CSSS has
been shown to open hair follicles for penetration and may
represent a valuable tool to enhance the follicular penetration
of transcutaneously applied vaccine (Schaefer and Lademann,
2001). Furthermore, hair follicles are not only important entry
points but also important reservoirs for topically applied
compounds, and CSSS increases this reservoir function of the
hair follicle, that is, depots in the follicular duct may help to
maintain high local concentrations of vaccine over a
prolonged period of time (Lademann et al., 2001). Last but
not least, immunostimulatory effects, which have been
reported for conventional adhesive tape stripping, may also
occur after CSSS of the skin (Katoh et al., 1997; Choi and
Maibach, 2003). All these putative effects of CSSS are
currently under investigation in our laboratory. In this study,
we performed CSSS two times prior to the transcutaneous
application of nanoparticles.
From the presented studies, we conclude that only 40 nm
particles, but not 750 or 1,500 nm nanoparticles, may be
used to transcutaneously deliver active vaccine compounds,
via the hair follicle, into cutaneous APCs. Future experi-
mental studies with functional vaccine preparations will
further investigate the potential of particle-based vaccines in
transcutaneous vaccination.
MATERIAL AND METHODS
Tissue samples
Fresh skin samples (retroauricular region, breast), less than
24 hours after surgical excision, were obtained from healthy
volunteers undergoing plastic surgery after informed consent
approved by the Institutional Ethics Committee of the
Medical Faculty of the Charite´-Universita¨tsmedizin Berlin
and according to the ethical rules stated in the Declaration of
Helsinki Principles.
Immunofluorescence
For immunofluorescent staining, protein blocking (DAKO
protein block) was performed on acetone-fixed cryosections
for 1 hour at room temperature. The sections were then
incubated for 1 hour with anti-CD1a (1:50, DAKO) in human
serum (Biotest, Dreieich, Germany), followed by washing in
phosphate-buffered saline (PBS) and incubation with anti-
mouse-FITC (1:50, Vector Laboratories, Burlingame, CA) for
45 minutes. After the final washing, the sections were
mounted in VECTASHIELD Mounting Medium (Vector
Laboratories, Burlingame, CA) and analyzed by fluorescence
microscopy (BX60F3, Olympus, Hamburg, Germany).
Transcutaneous particles application
The skin samples were investigated macroscopically and
microscopically for tissue damage. Samples with damaged
epidermis were excluded from the study. The application
area (1 cm2 for microscopy studies, 10–16 cm2 for flow
cytometry studies depending on the size and the quality of
the skin samples) was delineated by a skin surface marker on
the skin samples, leaving safety margins of 0.5 cm to the
border of the tissue in order to avoid nonspecific penetration
of particles sideways into the tissue. Particles of 1,500 nm,
750 nm (Yellow Green, FluoresbriteTM Carboxylate Poly-
sciences Inc., Warrington, FL; excitation: 458 nm, emission:
540 nm), and 40 nm (red fluorescent FluoSpheres, Molecular
Probes, Eugene, OR; excitation: 580 nm, emission: 605 nm)
in PBS, pH 7.4, were sonicated for 3 minutes (Sonorex Super
RK102H, Bandelin, Berlin, Germany). Prior to the application
of beads, CSSS was performed twice as described elsewhere
(Toll et al., 2004) using superglue, UHU GmbH, Buehl/
Baden, Germany. Nanoparticles of 20 ml/cm2, 40 nm (0.1%,
5.681010 particles/ml), 750 nm (0.1%, 2.16107 particles/
ml), or 1,500 nm (0.1%, 1.35 106 particles/ml) in PBS, pH
7.4, were applied, respectively. The tissue samples were
incubated for 15–16 hours at 371C in a humidified chamber.
For studies on the penetration and the uptake of 40 nm
particles, skin samples from six different donors were
prepared, and for studies on the penetration and the uptake
of 750 and 1,500 nm particles, samples from three different
donors were prepared.
MACS separation of epidermal CD1cþ cells
Epidermal cell suspensions were generated as described
previously (Peiser et al., 2003), with slight modifications.
Briefly, dispase digestion (2.4 U/ml Dispase I, Roche,
Germany) was performed overnight at 41C, followed by
trypsinization in 0.025% trypsin, 1.5 mM CaCl2 in PBS, pH
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7.4, for 10 minutes at 371C. After resuspension, MACS
separation with anti-BDCA-1 (anti-CD1c) antibodies was
performed according to the manufacturer’s recommenda
tion (CD1c blood dendritic cell antigen (BDCA-1) Dendritic
Cell Isolation Kit, Miltenyi Biotec, Bergisch Gladbach,
Germany).
Flow cytometry of epidermal LCs after transcutaneous applica-
tion of particles
MACS-separated epidermal cells after transcutaneous appli-
cation of particles were stained with anti-CD1a-APC anti-
body. Skin samples from three different donors were used to
evaluate the uptake of transcutaneously applied 750 and
1,500 nm nanoparticles. Skin samples from six different
donors were analyzed to assess the uptake of transcuta-
neously applied nanoparticles and subsequently subjected to
flow cytometry using a FACS Calibur (Becton Dickinson,
Heidelberg, Germany). In total, 10,000 events in each sample
were analyzed using CellQuests software (Becton Dick-
inson, Heidelberg, Germany).
Flow cytometry of epidermal LC suspensions incubated in the
presence of 40, 750, or 1,500 nm nanoparticles
Nanoparticles of 40 nm (0.02%, 5.681010 particles/ml),
750 nm (0.02%, 2.16107 particles/ml), or 1,500 nm
(0.02%, 2.7106 particles/ml) were incubated with 7105
MACS-separated epidermal LCs in RPMI 1640, 15% fetal calf
serum, including penicillin and streptomycin. All samples
were incubated for 2.5 hours at 371C or at 01C as indicated.
Cells were washed in PBS, stained with anti-CD1a-APC
antibody, and analyzed by flow cytometry as described
above. All experiments were carried out in triplicates.
Fluorescence microscopy and confocal laser scan microscopy
Prior to the freezing of the tissue blocks treated with
fluorescent nanoparticles, adhesive tape stripping was
performed five times on the skin surface to remove the
remaining nanoparticles from the skin surface and to reduce
the amount of free nanoparticles on the tissue section. The
investigational skin area of 1 cm2 was excised from the tissue
blocks and split into four squares of 0.50.5 cm2. Cryosec-
tions of 5 mm (2800 Frigocut-N, Reichert-Jung, Heidelberg,
Germany) were prepared from each block. As in previous
studies by our group (Toll et al., 2004), cutting was performed
with fresh blades from the dermis side towards the epidermis
in order to avoid dislocation of nanoparticles from the skin
surface on the section. The sections (20 sections per donor,
six different donors) were screened by fluorescence micro-
scopy (BX60F3, Olympus, Hamburg, Germany). Sections
containing longitudinal sections of vellus hair follicles (26
hair follicles from three different donors in total) were
selected for confocal laser scan microscopy analyses (LSM
410 invert, Zeiss, Jena, Germany). Digital image overlay
was used to localize the fluorescent signal on the tissue
sections.
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